^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    catadegbrutinib (BGB-16673)

    i
    Other names: BGB-16673, BGB16673, BGB 16673
    Associations

    News

    Trials
    Company:
    BeOne Medicines
    Drug class:
    BTK degrader
    Related drugs:
    Associations

    News

    Trials
    6d
    BGB-16673-102: Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (clinicaltrials.gov)
    P1/2, N=146, Recruiting, BeiGene | Trial completion date: Sep 2027 --> Jan 2029 | Trial primary completion date: Feb 2026 --> Jan 2029
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    19d
    A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)
    2ms
    BGB-16673-104: A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Patients With Relapsed or Refractory B-Cell Malignancies (2024-516234-35-00)
    P1/2, N=99, Recruiting, BeOne Medicines AG
    New P1/2 trial
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Lunsumio (mosunetuzumab-axgb) • sonrotoclax (BGB-11417) • Columvi (glofitamab-gxbm) • catadegbrutinib (BGB-16673)
    2ms
    BGB-16673-304: A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma. (2025-522860-34-00)
    P2/3, N=196, Recruiting, BeOne Medicines AG
    New P2/3 trial
    |
    Jaypirca (pirtobrutinib) • catadegbrutinib (BGB-16673)
    2ms
    ALLG NHL43: An open-label multi-centre international phase 2 trial to evaluate the safety and efficacy of two years fixed duration therapy with sonrotoclax in combination with the BGB-16673 and rituximab in patients with treatment naïve or BTKi naïve/intolerant Waldenström Macroglobulinemia (WM). (ACTRN12626000174381)
    P2, N=80, Not yet recruiting, Australasian Leukaemia and Lymphoma Group
    New P2 trial
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Rituxan (rituximab) • sonrotoclax (BGB-11417) • catadegbrutinib (BGB-16673)
    3ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, BeiGene | Recruiting --> Active, not recruiting | Trial completion date: Sep 2026 --> Apr 2026 | Trial primary completion date: Sep 2026 --> Apr 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    5ms
    Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants (clinicaltrials.gov)
    P1, N=37, Completed, BeiGene | Recruiting --> Completed
    Trial completion
    |
    itraconazole • catadegbrutinib (BGB-16673)
    6ms
    Invasive Cutaneous Mucormycosis in a Patient With Chronic Lymphocytic Leukemia on Obinutuzumab, Idelalisib, and Bruton Tyrosine Kinase Degrader: A Case Report. (PubMed, Cureus)
    We present a case of invasive cutaneous mucormycosis in an elderly man with chronic lymphocytic leukemia (CLL), who was receiving a Bruton tyrosine kinase (BTK)-targeted protein degrader trial drug (BGB-16673), obinutuzumab, a newer anti-CD20 monoclonal therapy, and idelalisib, a phosphoinositide 3-kinase inhibitor. Clinical cure was achieved with limb amputation, given the extent of disease. This case underscores the necessity of a low index of suspicion for mucormycosis on presentation, critical appraisal of the patient's risk factors, and a multimodal approach to diagnosis.
    Journal
    |
    BTK (Bruton Tyrosine Kinase)
    |
    Gazyva (obinutuzumab) • Zydelig (idelalisib) • catadegbrutinib (BGB-16673)
    7ms
    CaDAnCe-101: A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=614, Recruiting, BeiGene | Trial completion date: Dec 2028 --> Nov 2029 | Trial primary completion date: Dec 2025 --> Nov 2026
    Trial completion date • Trial primary completion date
    |
    catadegbrutinib (BGB-16673)
    7ms
    BGB-16673-304: A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P3, N=500, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jaypirca (pirtobrutinib) • catadegbrutinib (BGB-16673)
    10ms
    A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria (clinicaltrials.gov)
    P1, N=27, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    catadegbrutinib (BGB-16673)
    10ms
    CaDAnCe-303: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (clinicaltrials.gov)
    P3, N=150, Recruiting, BeiGene | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Rituxan (rituximab) • bendamustine • catadegbrutinib (BGB-16673)